Treatment of Naoxueshu Promotes Improvement of Hematoma Absorption and Neurological Function in Acute Intracerebral Hemorrhage Patients

Song, Juexian; Lyu, Yi; Wang, Pingping; Nie, Yuting; Lu, Huiqiang; Gao, Li; Tong, Xiaolin

doi:10.3389/fphys.2018.00933

Cited by 12 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study found anti‐inflammatory effects of Naoxueshu because the level of white blood cell (WBC) count was decreased more significantly in Naoxueshu treatment patients (Song et al., 2018). However, in this study, change of WBC count was not so significant.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Naoxueshu relieves hematoma after clot removal in acute spontaneous intracerebral hemorrhage

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objectives Surgical treatment is expected to remove clot immediately in acute spontaneous intracerebral hemorrhage (SICH) patients. The aim of this study was to evaluate whether Naoxueshu could enhance the efficacy of clot removal surgery in acute SICH patients. Methods One hundred twenty patients who had been diagnosed as SICH according to neuroimaging were enrolled in this study. They received craniotomy, decompressive craniectomy, or minimally invasive surgical evacuation as appropriate and then were randomized into two groups: the Naoxueshu group (NXS group, n = 60) and the control group (n = 60). All the patients received standard medical management while patients in NXS group also took Naoxueshu oral liquid 10 ml with three times a day for seven consecutive days. The primary outcome was the 7‐day hematoma volume and secondary outcomes were 7‐day National Institutes of Health Stroke Scale (NIHSS) score and 7‐day cerebral edema score. Results After clot removal surgery, hematoma volume in NXS group (9.5 ± 8.0) was significantly decreased than that in Control group (21.3 ± 22.9, p < .0001) 7 days after surgery. Moreover, cerebral edema was also relieved after 7‐day's Naoxueshu treatment (2.5 ± 0.9 vs. 2.9 ± 0.7, p = .043). Since patients in NXS group had worse baseline NIHSS score (17.2 ± 8.1 vs. 13.7 ± 10.1, p = .039), it was reasonable to conclude that Naoxueshu treatment could improve patients’ neurological function because 7‐day NIHSS score of the two groups was similar. Conclusion Naoxueshu oral liquid could relieve hematoma volume and cerebral edema after clot removal surgery in acute SICH patients. Moreover, it had the potential to improve patients’ short‐term neurological function.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Hematoma volume (ml) = π /6 × length (cm) × width (cm) × high (cm) (Song et al., 2018), and it was determined by CT scanning (Siemens 64‐slice CT machine, section thickness, 5 mm; gap, 5 mm; pitch, 1; tube current, 304mA; and voltage, 120 kV).…”

Section: Methodsmentioning

confidence: 99%

Naoxueshu relieves hematoma after clot removal in acute spontaneous intracerebral hemorrhage

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The NIHSS rater was an independent investigator who was blinded of our study in each site. Hematoma volume (ml) = π/6 × length (cm) × width (cm) × high (cm) [ 14 ], and it was determined by CT scanning (Siemens 64-slice CT machine, section thickness, 5 mm; gap, 5 mm; pitch, 1; tube current, 304 mA; and voltage, 120 kV).…”

Section: Methodsmentioning

confidence: 99%

Efficacy of Naoxueshu in acute spontaneous intracerebral hemorrhage: a multicenter observational study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety outcome and related risk factors of Naoxueshu in the treatment of acute SICH. Methods Two hundred twenty patients were enrolled in this study. Diagnosis of SICH was based on neuroimaging. All the patients received regular treatment and Naoxueshu oral liquid 10 ml 3 times a day for 14 consecutive days. Surgical intervention was conducted as needed. Efficacy and safety outcomes were evaluated. Results Hematoma volume decreased significantly 7 days after Naoxueshu treatment (from 27.3 ± 20.0 to 15.1 ± 15.1 ml, P < 0.0001), and it decreased further in 14-day result (6.9 ± 10.4 ml, P < 0.0001). Patients’ neurological function was improved remarkably with NIHSS scores from baseline 13 points to 7-day 7 points (P < 0.0001) and 14-day 4 points (P < 0.0001). Cerebral edema was relieved only 14 days after Naoxueshu treatment (from 3 to 2 points, P < 0.0001). No clinically significant change was found in 7-day and 14-day safety results. Female sex was related independently to large 7-day hematoma volume and worse 7-day NIHSS score while it would not affect patients’ 14-day outcomes. Rare cause of SICH (B = 17.4, P = 0.009) alone was related to large 14-day hematoma volume. Worse baseline NIHSS score (B = 0.3, P = 0.003) and early use of Naoxueshu (B = 2.9, P = 0.005) were related to worse 7-day and14-day neurological function. Conclusion Naoxueshu oral liquid could relieve hematoma volume and cerebral edema safely; meanwhile, it could improve patients’ neurological function. Sex, cause of SICH, and time from onset to receive Naoxueshu should be taken into consideration in the treatment of SICH.

show abstract

“…In the eld of traditional Chinese medicine (TCM), more and more attention was xed on the therapy of stroke, especially hemorrhagic stroke [8]. Song et al found that Naoxueshu oral liquid can signi cantly reduce the in ammation and edema of ICH [9]. And Li et al reported that tsRNAs may be the potential targets for Buyang Huanwu Decoction against ICH [10].…”

Section: Introductionmentioning

confidence: 99%

Network Pharmacology Integrated Molecular Docking Reveals the Mechanism of Zhongfeng Xingnao Formula against Intracerebral Hemorrhage

Wan

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Previous studies have shown that Zhongfeng Xingnao Formula (ZXF) can effectively reduce the mortality of intracerebral hemorrhage (ICH), but the underlying mechanism of the treatment remained still unexplored. This study aimed to expound the potential mechanism of ZXF in the treatment of ICH through network pharmacology and molecular docking.Methods: The putative targets of ZXF were obtained from the TCMSP and Uniprot database, while the potential targets of ICH received from Drugbank, Genecards and OMIM database. Then through the Venn 2.1, the overlapping targets of disease and drug were gotten for the further study. The GO and KEGG enrichment analyses were performed by R version 4.0.2 software so that the signaling pathway was acquired to the subsequent analysis. Cytoscape was used to construct the drug-compound-target-pathway network and String was utilized for the protein-protein interaction network. What’s more, the interaction between compound and target was verified by the AutoDockTools and Autodock Vina. Results: There were a total of 166 ZXF-related targets and 1258 ICH-related targets obtained from the public databases. And 87 potential targets were both related to drug and disease. The GO enrichment analysis mainly involved receptor ligand activity, signaling receptor activator activity, and cytokine receptor binding, while the signaling pathway, such as Fluid shear stress and atherosclerosis, AGE-RAGE signaling pathway in diabetic complications, PI3K-Akt signaling pathway, were significantly enriched in the KEGG enrichment analysis. The molecular docking elucidated that the aloe-emodin, beta-sitosterol, quercetin could bound well to the top five targets sorted by degree value.Conclusions: ZXF treated ICH through multiple compounds, multiple targets, and multiple pathways. The underlying mechanism of the treatment may be promoting angiogenesis, anti-inflammatory, anti-oxidative stress, and reversing atherosclerosis, which is of great significance for the treatment of ICH.

show abstract

Treatment of Naoxueshu Promotes Improvement of Hematoma Absorption and Neurological Function in Acute Intracerebral Hemorrhage Patients

Cited by 12 publications

References 17 publications

Naoxueshu relieves hematoma after clot removal in acute spontaneous intracerebral hemorrhage

Naoxueshu relieves hematoma after clot removal in acute spontaneous intracerebral hemorrhage

Efficacy of Naoxueshu in acute spontaneous intracerebral hemorrhage: a multicenter observational study

Network Pharmacology Integrated Molecular Docking Reveals the Mechanism of Zhongfeng Xingnao Formula against Intracerebral Hemorrhage

Contact Info

Product

Resources

About